iTeos Therapeutics, Inc. (ITOS)
NASDAQ: ITOS · Real-Time Price · USD
8.05
+0.20 (2.60%)
Nov 21, 2024, 1:52 PM EST - Market open
iTeos Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 |
| Revenue | 35 | 12.6 | 267.63 | 344.78 | - | - | Upgrade
|
| Revenue Growth (YoY) | -47.37% | -95.29% | -22.38% | - | - | - | Upgrade
|
| Gross Profit | 35 | 12.6 | 267.63 | 344.78 | - | - | Upgrade
|
| Selling, General & Admin | 49.64 | 50.4 | 43.95 | 40.51 | 15.34 | 8.84 | Upgrade
|
| Research & Development | 131.45 | 109.77 | 96.19 | 59.37 | 29.61 | 18.42 | Upgrade
|
| Operating Expenses | 181.09 | 160.17 | 140.13 | 99.87 | 44.95 | 27.26 | Upgrade
|
| Operating Income | -146.09 | -147.57 | 127.5 | 244.9 | -44.95 | -27.26 | Upgrade
|
| Interest & Investment Income | 31.06 | 31.77 | 11.36 | 0.08 | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | 2.87 | 6.77 | 9.88 | 11.49 | 6.86 | 4.92 | Upgrade
|
| Pretax Income | -112.17 | -109.03 | 148.74 | 256.46 | -38.09 | -22.34 | Upgrade
|
| Income Tax Expense | 9.08 | 3.61 | 52.08 | 41.94 | -0.06 | 0.12 | Upgrade
|
| Net Income | -121.25 | -112.64 | 96.65 | 214.52 | -38.03 | -22.45 | Upgrade
|
| Preferred Dividends & Other Adjustments | - | - | - | - | 5.37 | 4.08 | Upgrade
|
| Net Income to Common | -121.25 | -112.64 | 96.65 | 214.52 | -43.4 | -26.54 | Upgrade
|
| Net Income Growth | - | - | -54.95% | - | - | - | Upgrade
|
| Shares Outstanding (Basic) | 39 | 36 | 36 | 35 | 15 | 0 | Upgrade
|
| Shares Outstanding (Diluted) | 39 | 36 | 38 | 38 | 15 | 0 | Upgrade
|
| Shares Change (YoY) | 8.15% | -5.30% | -0.02% | 150.49% | 7336.29% | 9.20% | Upgrade
|
| EPS (Basic) | -3.14 | -3.15 | 2.72 | 6.10 | -2.88 | -130.85 | Upgrade
|
| EPS (Diluted) | -3.14 | -3.15 | 2.56 | 5.68 | -2.88 | -130.85 | Upgrade
|
| EPS Growth | - | - | -54.93% | - | - | - | Upgrade
|
| Free Cash Flow | -120.32 | -106.72 | -112.13 | 511.96 | -25.53 | -23.87 | Upgrade
|
| Free Cash Flow Per Share | -3.12 | -2.98 | -2.97 | 13.55 | -1.69 | -117.69 | Upgrade
|
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | - | - | Upgrade
|
| Operating Margin | -417.41% | -1171.69% | 47.64% | 71.03% | - | - | Upgrade
|
| Profit Margin | -346.44% | -894.34% | 36.11% | 62.22% | - | - | Upgrade
|
| Free Cash Flow Margin | -343.77% | -847.34% | -41.90% | 148.49% | - | - | Upgrade
|
| EBITDA | -144.95 | -146.68 | 128.3 | 245.5 | -44.42 | -26.65 | Upgrade
|
| EBITDA Margin | - | - | 47.94% | 71.21% | - | - | Upgrade
|
| D&A For EBITDA | 1.14 | 0.9 | 0.8 | 0.6 | 0.54 | 0.61 | Upgrade
|
| EBIT | -146.09 | -147.57 | 127.5 | 244.9 | -44.95 | -27.26 | Upgrade
|
| EBIT Margin | - | - | 47.64% | 71.03% | - | - | Upgrade
|
| Effective Tax Rate | - | - | 35.02% | 16.35% | - | - | Upgrade
|
| Revenue as Reported | 35 | 12.6 | 267.63 | 344.78 | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.